Shionogi Plans Greater Presence In U.S., U.K. Markets
This article was originally published in PharmAsia News
Japan's Shionogi plans to concentrate on the foreign market with an aim to triple the foreign share of its overall sales. Foreign business currently accounts for only 10 percent of Shionogi sales and its goal is to boost that amount to 30 percent. The firm plans to create a wholly owned subsidiary for development in the United Kingdom and apply for approval of three products in the United States in 2011. To market those drugs two years later, Shionogi is considering acquisition of a midsize U.S. drug maker. The drugs include its first product developed abroad, an obesity treatment, now in Phase III trials. (Click here for more - a subscription may be required
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.